UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Atomic and Molecular Layer Deposition of Chiral Thin Films Showing up to 99% Spin Selective Transport

Nano letters, 2022-06, Vol.22 (12), p.5022-5028

2022

Volltextzugriff (PDF)

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Annals of oncology, 2020-11, Vol.31 (11), p.1526-1535

2020

Volltextzugriff (PDF)

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Annals of oncology, 2018-09, Vol.29 (9), p.1939-1947

2018

Volltextzugriff (PDF)

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

Leukemia, 2006-02, Vol.20 (2), p.322-328

2006

Volltextzugriff (PDF)

Breast carcinoma—rare types: review of the literature

Annals of oncology, 2009-11, Vol.20 (11), p.1763-1770

2009

Volltextzugriff (PDF)

Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome

Annals of oncology, 2012-02, Vol.23 (2), p.338-345

2012

Volltextzugriff (PDF)

Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial

Annals of oncology, 2023-12, Vol.34 (12), p.1141-1151

2023

Volltextzugriff (PDF)

Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced

Leukemia, 2013-04, Vol.27 (4), p.829-835

2013

Volltextzugriff (PDF)

Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies

Bone marrow transplantation (Basingstoke), 2015-12, Vol.50 (12), p.1526-1535

2015

Volltextzugriff (PDF)

Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity

Bone marrow transplantation (Basingstoke), 2012-10, Vol.47 (10), p.1274-1282

2012

Volltextzugriff (PDF)

POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA

Hematological oncology, 2023-06, Vol.41 (S2), p.82-83

2023

Volltextzugriff (PDF)

Malignancy associated SIADH: Characterization and clinical implications

Acta oncologica, 2016-10, Vol.55 (9-10), p.1190-1195

2016

Volltextzugriff (PDF)

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations

Breast cancer research and treatment, 2016-06, Vol.157 (3), p.511-516

2016

Volltextzugriff (PDF)

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up

Leukemia, 2010-05, Vol.24 (5), p.1050-1052

2010

Volltextzugriff (PDF)

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

Annals of oncology, 2017-07, Vol.28 (7), p.1560-1568

2017

Volltextzugriff (PDF)

Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?

Annals of oncology, 2012-04, Vol.23 (4), p.876-881

2012

Volltextzugriff (PDF)

P169 Clinical outcomes in patients (pts) with estrogen receptor (ER)+ stage I breast cancer (BC) and Recurrence Score (RS) 26–30: Real-world data

Breast (Edinburgh), 2023-04, Vol.68, p.S81-S82

2023

Volltextzugriff (PDF)

Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2016-10, Vol.51 (10), p.1313-1317

2016

Volltextzugriff (PDF)

PAGET'S DISEASE AND MALE BREAST CANCER

The Israel Medical Association journal, 2015-06, Vol.17 (6), p.396-396

2015

Volltextzugriff (PDF)

Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis

Journal of neuro-oncology, 2013-09, Vol.114 (2), p.229-235

2013

Volltextzugriff (PDF)

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

Annals of oncology, 2018-10, Vol.29, p.viii96-viii97

2018

Volltextzugriff (PDF)

PATIENTS WITH OUT OF SPECIFICATION TISAGENLECLEUCEL CAN BE SALVAGED WITH A POINT‐OF‐CARE CAR T‐CELLS: AN OBSERVATIONAL INTENTION‐TO‐TREAT SINGLE‐CENTER ANALYSIS

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine busulfan

Leukemia, 2007-10, Vol.21 (10), p.2109-2116

2007

Volltextzugriff (PDF)

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

Annals of oncology, 2018-10, Vol.29, p.viii96-viii96

2018

Volltextzugriff (PDF)

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines

British journal of cancer, 2005-05, Vol.92 (10), p.1881-1891

2005

Volltextzugriff (PDF)

1 – 25 von 295

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(268)
Mit Volltextzugriff
(260)

Publikationsform

Artikel
(294)
Buchkapitel
(1)

Sprache

Englisch
(291)
Hebräisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(147)
Life Sciences & Biomedicine
(97)
Humans
(84)
Biological And Medical Sciences
(50)
Female
(50)
Physical Sciences
(43)
Male
(42)
Oncology
(41)
Adult
(39)
Medical Sciences
(38)
Middle Aged
(34)
Exact Sciences And Technology
(27)
Aged
(26)
Chemistry
(24)
Applied Sciences
(20)
Technology
(20)
Hematology
(19)
Hematology, Oncology And Palliative Medicine
(18)
Adolescent
(17)
Physics
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Atomic and Molecular Layer Deposition of Chiral Thin Films Showing up to 99% Spin Selective Transport

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

Breast carcinoma—rare types: review of the literature

Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome

Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial

Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced

Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies

Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity

POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA

Malignancy associated SIADH: Characterization and clinical implications

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?

P169 Clinical outcomes in patients (pts) with estrogen receptor (ER)+ stage I breast cancer (BC) and Recurrence Score (RS) 26–30: Real-world data

Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation

PAGET'S DISEASE AND MALE BREAST CANCER

Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

PATIENTS WITH OUT OF SPECIFICATION TISAGENLECLEUCEL CAN BE SALVAGED WITH A POINT‐OF‐CARE CAR T‐CELLS: AN OBSERVATIONAL INTENTION‐TO‐TREAT SINGLE‐CENTER ANALYSIS

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines

Suchergebnisse filtern